
Daito Pharmaceutical Co Ltd
TSE:4577

Net Margin
Daito Pharmaceutical Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
JP |
![]() |
Daito Pharmaceutical Co Ltd
TSE:4577
|
33.4B JPY |
6%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
782.6B USD |
24%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
399.2B USD |
16%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
231.6B CHF |
20%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
198.1B CHF |
23%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
174.5B GBP |
13%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
227.3B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
143B USD |
13%
|
Daito Pharmaceutical Co Ltd
Glance View
Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Daito Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of 5.6%.